Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
53 studies found for:    " September 15, 2009":" October 15, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed
Has Results
Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels
Conditions: HIV Infections;   Dyslipidemia;   Endothelial Dysfunction
Intervention: Drug: extended release niacin
22 Completed Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
Conditions: Malaria;   HIV Infections
Interventions: Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Zidovudine;   Drug: Lamivudine
23 Completed Pharmacokinetics of Lamivudine at Two Different Doses
Condition: HIV Infections
Intervention: Drug: Lamivudine (3TC)
24 Active, not recruiting Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons
Conditions: Influenza;   HIV Infections
Intervention:
25 Completed Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV
Condition: HIV Infections
Intervention: Drug: Raltegravir
26 Completed Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
Condition: HIV Infections
Interventions: Drug: Darunavir/ritonavir;   Drug: Lopinavir/ritonavir
27 Unknown  Effect of Rosuvastatin on Endothelial Function
Conditions: HIV Infections;   Cardiovascular Disease
Intervention: Drug: rosuvastatin
28 Completed Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort
Condition: HIV Infections
Intervention:
29 Completed Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients
Conditions: HIV Infections;   Lipoatrophy
Interventions: Drug: EFV;   Drug: LPV/r
30 Completed
Has Results
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Conditions: HIV Infection;   Hepatitis C Infection
Interventions: Drug: Nitazoxanide (NTZ);   Drug: Pegylated interferon alfa-2a (PEG);   Drug: Ribavirin (RBV)
31 Completed Mothers Living With HIV and Their Adolescent Children
Conditions: Family Relations;   Mental Health;   Physical Health;   Risky Sexual Behavior;   Substance Use;   HIV Infections
Intervention: Behavioral: Cognitive-behavioral, small-group format sessions
32 Completed QoL and Adherence to One-pill Once-a-day HAART
Conditions: HIV Infection;   HIV Infections
Intervention: Other: reduced number of pills
33 Completed
Has Results
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Conditions: HIV-1 Infection;   HIV Infections
Interventions: Drug: maraviroc;   Drug: darunavir;   Drug: ritonavir
34 No longer available A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Open Label Treatment Access: Maraviroc
35 Completed Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
Condition: HIV
Interventions: Drug: HAART;   Drug: HAART + Immunotherapy
36 Completed
Has Results
Cardiovascular Prevention for Persons With HIV
Conditions: HIV Infection;   Cardiovascular Disease Risk
Interventions: Drug: Pravastatin;   Drug: Lisinopril
37 Completed Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL);   Drug: Atazanavir (ATV);   Drug: Ritonavir (RTV);   Drug: Tenofovir (TDF);   Drug: Etravirine (ETV);   Drug: Darunavir (DRV);   Drug: Maraviroc (MVC);   Drug: Lopinavir/ritonavir (LPV/r)
38 Completed
Has Results
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
Conditions: Hepatitis C;   HIV Infections
Interventions: Drug: telaprevir or matching placebo;   Biological: peginterferon alfa-2a;   Drug: ribavirin (fixed dose);   Drug: ribavirin (weight-based dose)
39 Completed
Has Results
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
Condition: HIV Infections
Interventions: Drug: Ribavirin;   Drug: Raltegravir
40 Active, not recruiting Durability of Adherence in Self-Management of HIV (The DASH Study)
Condition: HIV Infections
Intervention: Behavioral: Modified client adherence profiling and intervention tailoring (CAP-IT)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Indicates status has not been verified in more than two years